Correlation of multiple endpoints in the first‐line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials

作者：Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii · 发表于：Cancer Medicine · 年份：2023 · DOI：10.1002/cam4.6818 · 被引用次数：3 · 研究领域：Gastric Cancer Management and Outcomes、Head and Neck Cancer Studies、Cholangiocarcinoma and Gallbladder Cancer Studies

BACKGROUND: Individual-level surrogates are important for management in patients treated for advanced gastric cancer (AGC). This study aimed to comprehensively investigate the correlation of multiple clinical endpoints in the first-line chemotherapy of AGC. METHODS: Individual patient data (IPD) were collected from four Japanese Phase III trials comparing S-1-based first-line chemotherapies (SPIRITS, START, GC0301/TOP-002, and G-SOX trials). Patients without Response Evaluation Criteria in Solid Tumors (RECIST)-based radiological assessments were excluded. Spearman's rank correlation coefficient was tested for correlation among overall survival (OS), progression-free survival (PFS), and postprogression survival (PPS). OS, PFS, and PPS were compared between responders (best response: complete response or partial response) and nonresponders (best response: stable disease or progressive disease). RESULTS: The study included a total of 1492 patients. Eighty percent of the patients (n = 1190) received subsequent chemotherapies after the failure of each trial's treatment protocol. PFS moderately correlated with OS (Spearman correlation coefficient = 0.66, p < 0.005), whereas the correlation between PPS and OS was strong (Spearman correlation coefficient = 0.87, p < 0.005). Responders had significantly longer OS (median, 17.7 vs. 9.1 months, p < 0.005), PFS (median, 6.9 vs. 2.8 months, p < 0.005), and PPS (median, 10.5 vs. 6.0 months, p < 0.005) than nonresponders. CONCLUSIONS: Our ...